Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs Tango Therapeutics Inc. — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.44 (market cap $3.38B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF and Tango Therapeutics Inc. are close in size by market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SP Funds S&P 500 Sharia Industry Exclusions ETF for 66 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPUS | TNGX | |
|---|---|---|
Market Cap | $3.38B | $3.74B |
Volume | 362,932 | 3,438,781 |
Sector | Broad Market / Factor | Health |
52-Week High | $61.15 | $32.90 |
52-Week Low | $46.65 | $7.50 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $60.53, showing minimal daily movement with a slight decline of 0.07%. Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains regular dividend distributions, with recent payments of $0.03 per share. Short interest saw significant growth in September, increasing 174.5% to 257,142 shares as of September 15, 2026.
The ETF's technical strength supports near-term upside potential, though elevated short interest indicates some bearish sentiment. Dividend consistency provides income appeal, but investors should monitor the growing short position which could increase volatility. The neutral oscillator readings suggest potential consolidation before further directional movement.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
